Edith Cowan University

Research Online
Research outputs 2014 to 2021
12-14-2018

Clinical and genetic associations of renal function and diabetic
kidney disease in the United Arab Emirates: A cross-sectional
study
Wael M. Osman
Herbert F. Jelinek
Guan K. Tay
Edith Cowan University

Ahsan H. Khandoker
Kinda Khalaf

See next page for additional authors

Follow this and additional works at: https://ro.ecu.edu.au/ecuworkspost2013
Part of the Endocrinology, Diabetes, and Metabolism Commons
10.1136/bmjopen-2017-020759
Osman, W.M., Jelinek, H.F., Tay, G.K., Khandoker, A.H., Khalaf, K., Almahmeed, W., ... Alsafar, H.S. (2018). Clinical and
genetic associations of renal function and diabetic kidney disease in the United Arab Emirates: A cross-sectional
study. Diabetes and Endocrinology Research, 8, e020759.
Available here.
This Journal Article is posted at Research Online.
https://ro.ecu.edu.au/ecuworkspost2013/5485

Authors
Wael M. Osman, Herbert F. Jelinek, Guan K. Tay, Ahsan H. Khandoker, Kinda Khalaf, Wael Almahmeed,
Mohamed H. Hassan, and Habiba S. Alsafar

This journal article is available at Research Online: https://ro.ecu.edu.au/ecuworkspost2013/5485

Open access

Research

Wael M Osman,1 Herbert F Jelinek,2,3 Guan K Tay,1,4,5,6 Ahsan H Khandoker,6
Kinda Khalaf,6 Wael Almahmeed,7,8 Mohamed H Hassan,9 Habiba S Alsafar1,6

To cite: Osman WM, Jelinek HF,
Tay GK, et al. Clinical and
genetic associations of
renal function and diabetic
kidney disease in the United
Arab Emirates: a crosssectional study. BMJ Open
2018;8:e020759. doi:10.1136/
bmjopen-2017-020759
►► Prepublication history for
this paper is available online.
To view these files, please visit
the journal online (http://dx.doi.
org/10.1136/bmjopen-2017-
020759).

Received 26 November 2017
Revised 18 October 2018
Accepted 20 November 2018

© Author(s) (or their
employer(s)) 2018. Re-use
permitted under CC BY-NC. No
commercial re-use. See rights
and permissions. Published by
BMJ.
For numbered affiliations see
end of article.
Correspondence to
Dr Habiba S Alsafar;
habiba.alsafar@ku.ac.a e

Abstract
Objectives Within the Emirati population, risk factors and
genetic predisposition to diabetic kidney disease (DKD)
have not yet been investigated. The aim of this research
was to determine potential clinical, laboratory and reported
genetic loci as risk factors for DKD.
Research design and methods Four hundred and ninety
unrelated Emirati nationals with type 2 diabetes mellitus
(T2DM) were recruited with and without DKD, and clinical
and laboratory data were obtained. Following adjustments
for possible confounders, a logistic regression model was
developed to test the associations of 63 single nucleotide
polymorphisms (SNPs) in 43 genetic loci with DKD (145
patients with DKD and 265 without DKD). Linear regression
models, adjusted for age and gender, were then used to
study the genetic associations of five renal function traits,
including 83 SNPs with albumin-to-creatinine ratio, 92
SNPs with vitamin D (25-OH cholecalciferol), 288 SNPs
with estimated glomerular filtration rate (eGFR), 363 SNPs
with serum creatinine and 73 SNPs with blood urea.
Results Patients with DKD, as compared with those
without the disease, were mostly men (52%vs38% for
controls), older (67vs59 years) and had significant rates
of hypertension and dyslipidaemia. Furthermore, patients
with DKD had T2DM for a longer duration of time (16vs10
years), which in an additive manner was the single
factor that significantly contributed to the development
of DKD (p=0.02, OR=3.12, 95% CI 1.21 to 8.02). Among
the replicated associations of the genetic loci with
different renal function traits, the most notable included
SHROOM3 with levels of serum creatinine, eGFR and DKD
(Padjusted=0.04, OR=1.46); CASR, GC and CYP2R1 with
vitamin D levels; as well as WDR72 with serum creatinine
and eGFR levels.
Conclusions Associations were found between several
genetic loci and risk markers for DKD, which may
influence kidney function traits and DKD in a population of
Arab ancestry.

Introduction
This overall dramatic worldwide increase in
the number of people with diabetes has had
a major impact on the increasing incidence
and prevalence of diabetic kidney disease

Strengths and limitations of this study
►► This cross-sectional study to determine the clini-

cal, laboratory and genetic associations of diabetic
kidney disease (DKD) and renal function traits in a
sample of patients with type 2 diabetes mellitus was
the first of its kind in a population of Arab ancestry
from the United Arab Emirates.
►► A limitation inherent to this study was that the analyses carried out did not include treatment modalities
due to patients having multiple conditions and treatments, which made the models largely unstable and
difficult to interpret.
►► Current analyses of the DKD genetic association had
a statistical power of ~57%, suggesting that a larger
population sample across the Middle East is required
to discover novel clinical and genetic predisposition
to DKD in the region with better statistical power.

(DKD) as one of the most frequent complications of both types of diabetes. Globally, the
prevalence of chronic kidney disease (CKD)
among adults in the general population is
reported to be around 10%.1 However, 20%
of adults with type 2 diabetes mellitus (T2DM)
are expected to develop DKD based on estimated glomerular filtration rate (eGFR)
measurements (<60 mL/min/1.73 m2), while
the number reaches 30%–50% based on
the urinary albumin excretion levels.1 This
considerable variation is due to variances in
settings, geographical area and ethnicity.2
Overall, the risk of DKD in T2DM is approximately 2% per year.3 In the Arab world, the
prevalence of DKD is also highly variable
(10.8%–61.2%)%) depending on the study
design, population, sample selection, race,
age, sex, as well as diagnostic criteria among
other factors.4 Meta-analysis has shown that
DKD is the leading cause of end-stage renal
disease (ESRD) in the Gulf Cooperation
Council (GCC) with a prevalence of ~17%.5
Patients with ESRD have a 20% annual
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the loss of renal function in patients with T2DM, in addition to the established risk factors for DKD such as age,
sex, diabetes duration, HbA1c, blood pressure, baseline
eGFR and albumin-to-creatinine ratio.26 However, issues
such as whether the levels of these markers are affected
by genetic variations, and whether the encoding genes
contribute to DKD development and progress need
further investigation.
The United Arab Emirates (UAE) is among the countries with the highest prevalence rates of T2DM, obesity
and cardiovascular disease.27 28 AlSafar and colleagues
have recently reported that approximately 80% of patients
with T2DM within UAE present with at least one complication associated with T2DM, including kidney disease
(approximately 6%).29 Furthermore, there is increasing
evidence suggesting that the genome structure of individuals of Arabic descent is different from individuals from
other populations.30 Despite the high prevalence rate of
DKD in the UAE, there have been no investigations up to
date of the genetic associations of chronic kidney conditions and kidney functions, particularly as associated with
T2DM. Therefore, the current work aimed to investigate
the clinical and laboratory variables linked to DKD in a
T2DM Emirati population and to study the associations
of the reported genetic loci linked to different renal function tests in CKD and DKD.
Materials and methods
Study type and subjects
This work describes a cross-sectional study of Emirati
patients from the city of Abu Dhabi. The demographic
information and clinical data for the participants are
presented in tables 1 and 2. Four hundred and ninety
(n=490) patients with T2DM were included in the study,

Table 1 Baseline data of tested traits and tested SNPs
Trait

Mean±SD or
quartiles

N of subjects
(male/female)

ACR (mg/mmol)
Vitamin D (ng/mL)

1.05/3.9/12.7†
63.7±27.8

115 (56/59)
328 (146/182)

331
442

83
92

Age and gender.
Age and gender.

eGFR (ml/
min/1.73 m2)

81.5±28.5

395 (172/223)

1478

288

Age and gender.

Serum creatinine
(µmol/L)

60/74/95.8†

474 (246/228)

1792

363

Age and gender.

Blood urea
(mmol/L)
Diabetic kidney
disease

6.4±5.4

450 (263/214)

446

73

Age and gender.

288

63

Age, gender,
hypertension, T2DM
duration and eGFR
levels.

With: 145.
Without: 265.

N of SNPs
reported*

N of SNPs tested*

Covariates

*Reported means the total number of SNPs found in the search in the literature and tested means the actual number of SNPs found from the
reported SNPs and used for the analyses in this study for each corresponding trait.
†For the albumin:creatinine ratio (ACR) and creatinine analyses, summary statistics indicated by 25th/50th/75th quartiles and not as
mean±SD because their distributions are skewed.
eGFR, estimated glomerular filtration rate; SNPs, single nucleotide polymorphisms; T2DM, type 2 diabetes mellitus.
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mortality rate, which is higher than the rate for many
solid cancers.6 In addition to increasing the risk of cardiovascular morbidity and mortality7 8, DKD is reported to be
the single strongest predictor of mortality in patients with
diabetes,9 with a 5-year survival in the range of 30%.10
The current trend suggests that the prevalence of DKD
will continue to increase worldwide, leading to increased
morbidity and mortality and imposing significant socioeconomic burdens on global healthcare systems.11 A
thorough literature search reveals that there remains a
wide knowledge gap related to the understanding of risk
factors and pathophysiological mechanisms associated
with DKD, especially in the GCC and Middle East. Since
ESRD can only be treated with highly invasive and costly
procedures, such as dialysis or kidney transplantation,
better knowledge of genetic, clinical and epidemiological
factors associated with DKD is required to allow for timely
and more effective treatment options.
In clinical practice, renal function is assessed using a
number of tests that are reported to have high heritability
rates.12 This indicates that genetic factors contribute
significantly to interindividual variance in kidney function, and hence, to the susceptibility to CKD and related
conditions. Thus far, several genetic loci have been linked
to DKD, CKD and renal function traits in adults13–24 as
well as children.25 However, in comparison with other
diseases, including T2DM and other cardiometabolic
disorders, studies of kidney disease and kidney function
traits are largely insufficient and inconclusive. In spite of
efforts to describe novel biomarkers for DKD, currently no
tested candidates outperform albumin. A recent report
by Saulnier et al suggests that three serum biomarkers
(midregional-proadrenomedullin,
soluble
tumour
necrosis factor receptor 1 and N-terminal prohormone
brain natriuretic peptide) can improve risk prediction of

Open access

Type of variables

Variable

DKD

No DKD

P value*

Demographic variables
Gender: female†

70 (48.3)

165 (62.3)

0.006

Age (years)

67.0±10.4

58.6±10.6

<0.0001

Clinical hypertension †

96.6

74.3

<0.0001

Dyslipidaemia †

95.2

90.9

0.17

Clinical variables

Smoking history †

32.4

24.2

0.07

Diabetes duration (years)

16.0±9.2

10.1±7.3

<0.0001

BMI (kg/m2)

31.3±6.0

32.5±6.3

0.078

Hemoglobin A1c (%)

7.7±1.5

7.8±1.7

0.63

Laboratory variables
Glycaemic indices

Lipids profile

Fasting plasma glucose (mmol/L)

8.3±3.1

8.9±3.8

0.43

Random blood glucose (mmol/L)

9.1±3.9

9.5±4.3

0.34

Total cholesterol (mmol/L)

3.7±1.0

4.0±1.1

0.003

Triglyceride (mmol/L)

1.5±0.8

1.6±0.8

0.25

HDL-cholesterol (mmol/L)

1.2±0.6

1.2±0.5

0.45

LDL-cholesterol (mmol/L)

1.9±0.8

2.1±0.9

0.01

3.3/10.1/69.6

0.8/2.2/9.0

0.0001

62.9±28.4

65.3±26.8

0.48

Renal function indices Albumin:creatinine ratio (mg/mmol) ‡
Vitamin D (nmol/L)
2

eGFR (mL/min/1.73 m )

57.5±27.7

96.1±17.3

<0.0001

Creatinine (µmol/L) ‡
Urea (mmol/L)

82/111/146
9.7±8.3

55/64/76
4.7±1.5

<0.0001
<0.0001

*P value for continuous data, calculated using two-sided t-test except for albumin:creatinine ratio and creatinine where it is for Wilcoxon ranksum (Mann-Whitney) test. P value for percentage data calculated using Pearson χ2 test with exception of hypertension and dyslipidaemia
where Fisher’s exact test was used.
† Proportional data shown as number of positive outcome and its percentage. All remaining continuous data shown as mean±SD except
albumin:creatinine ratio and creatinine.
‡For the albumin:creatinine ratio and creatinine analyses, summary statistics indicated by 25th/50th/75 quartiles and not as mean±SD
because their distributions are highly skewed.
BMI, body mass index; DKD, diabetic kidney disease; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, highdensity lipoprotein; T2DM, type 2 diabetes mellitus.

with 145 diagnosed with DKD. The participants were
recruited from Sheikh Khalifa Medical City and Mafraq
Hospital, major tertiary hospitals in Abu Dhabi, UAE. All
subjects were UAE born and of Arabian descent.
Patient and public involvement
The study was designed because T2DM, along with its
multiorgan complications, is a major health challenge
in the UAE with increasingly growing public interest.
However, patients and the public at large were not
involved in defining the research questions, analyses,
interpretation or dissemination of the results.

either reported based on clinical records of the participants or diagnosed as previously indicated.31 The presence of T2DM was confirmed by a qualified physician
based on criteria outlined by the WHO.32 Trained nurses
measured the height and weight of each participant using
a calibrated wall-mounted stadiometer and a weight scale,
respectively. Body mass index was calculated as the weight
in kilograms divided by the square of the height in metres
(kg/m2).

Clinical variables and laboratory data
Various clinical and laboratory measures were collected/
assessed during the hospital visits. Blood pressure was
taken on two different occasions. Hypertension was
defined as systolic blood pressure ≥140 mm Hg, diastolic
blood pressure ≥90 mm Hg or if the patients were taking
any antihypertensive medications. Dyslipidaemia was

Diabetic kidney disease
DKD was defined as either decreased levels of eGFRestimated glomerular filtration rate (<60 mL/min/1.73 m2)
with or without renal damage over a period of at least
3 months,33 or based on an albumin-to-creatinine
ratio ≥30 mg/g, or proteinuria >500 mg over a 24-hour
period in the setting of T2DM and/or abnormalities,
as assessed by imaging or histology.34 eGFR was calculated according to CKD-EPI Creatinine Equation.35
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Table 2 Demographic, clinical and laboratory characteristics of T2DM patients with or without kidney disease
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Statistical modelling and analyses
Continuous variables were presented as mean±SD or
lower/median and upper quartiles where the distributions were highly skewed. Vitamin D and eGFR levels
were normally distributed. However, urea levels, creatinine levels and albumin-to-creatinine ratio data were

converted to normal distributions using natural log
transformation. The associations of trait values or their
natural logs (if transformed) were tested with SNPs
using linear regression models, which included age
and gender as covariates using PLINK software V.1.07
(http://zzz.bwh.harvard.edu/plink/). The same software was used for counting allele frequencies and
testing the quality control (QC) variables. Any SNPs with
minor allele frequency (MAF) <0.05, and >5% missing
genotype rate, or those that failed the Hardy-Weinberg
equilibrium (HWE) test at the 0.001 were excluded.
HWE is considered as an important QC test for genetic
association studies and assumes that allele and genotype frequencies can be estimated. If the frequencies
of the measured genotypes significantly differed from
the HWE assumptions, genotyping errors among other
possible factors, such as ethnic diversity and high levels
of consanguinity in the population, are indicated leading
to excluding the SNPs from further analyses. Association
with p<0.05 were reported, indicating the replication of
previously reported associations.
Statistical analyses for all clinical and laboratory variables were performed using Stata software V.14 . For
continuous data, statistical differences were assessed
using two-sided t-tests for normally distributed data or
the Wilcoxon rank-sum (Mann-Whitney) test for highly
skewed data. The Pearson χ2 test was used for percentage
data as well as the Fisher’s exact test when the expected
frequencies were less than 5. A p value<0.05 was considered as significant. PLINK software was also used for
testing the associations between the SNPs and DKD
using a case–control logistic regression model, which
included age, gender, hypertension status, T2DM duration and eGFR levels as covariates (table 1). The results
are presented as p values (Padjusted<0.05) and ORs with
corresponding 95% CIs. The same approach (patients
with DKD vs patients without DKD) was adopted to test
the associations between the possible risk factors and
the development of the DKD (table 3). However, the
logistic model, which included all the associated factors
listed in table 4 was validated by the Hosmer-Lemeshow
goodness of fit test (p=0.11) to allow for the inclusion
of several covariates. Analyses between SNPs and renal
function traits were conducted in PLINK using linear
regression models that included age and gender as
covariates. The results were presented as beta coefficients (regression coefficients for the linear regression
model, calculated based on the minor allele), standard
errors and p values.
As this was a replication study, we reported all p
values <0.05, suggesting possible replications. However,
using a Bonferroni correction for multiple testing, the
p values of some of the models with statistically significant associations included p<0.00079 for the DKD associations, p<0.0006 for the ACR, p<0.0005 for the vitamin
D, p<0.00017 for the eGFR, p<0.00019 for the creatinine
and p<0.00068 for associations with urea.
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Selection of SNPs
Genetic investigation in this study followed the candidate gene approach.36 The SNPs tested for each trait are
summarised in table 1. These SNPs were selected from
a recent Genome Wide Association Study (GWAS) that
was intended to determine the genetic associations of
T2DM in the UAE population towards establishing the
Emirates Family Registry for T2DM.27 The GWAS was
performed for 490 samples with T2DM and 450 healthy
controls using the Infinium Omni5ExomeHuman chip
(Illumina, San Diego, California, USA). To select the
SNPs associated with the kidney function traits included
in the study (blood urea, serum creatinine, eGFR values,
albumin-to-creatinine ratio and vitamin D levels) as well
as DKD, various search engines and data bases including
PubMed, Google Scholar, the GWAS catalogue (https://
www.ebi.ac.uk/gwas/home), the Phenolyzer database
(http://phenolyzer.wglab.org/), the infinome genome
interpretation platform (https://www.
infino.
me/) and
the GWAS Central database (http://www.
gwascentral.
org/) were consulted.
Our search strategy consisted of identifying reported
SNPs that cleared the GWAS significance level and were
found in our GWAS data. If the original signal SNP was
missing from the GWAS data, we searched for a possible
proxy SNP using the concept of linkage disequilibrium
(LD). This typically indicates a non-random association
of alleles at different genetic loci in a given population
and their tendency to be inherited as a block (mathematical values r2 and D′>0.8 indicates high LD). Proxy SNPs
were selected using the SNAP database for SNP Annotation and Proxy Search (http://archive.broadinstitute.
org/mpg/snap/ldsearch.php).
All SNPs located within and flanking genes that have
been previously reported in association with CKD and
DKD were included. In total, 43 genetic loci were identified as linked to CKD, DKD or a decline in renal function. Specifically, the gene loci comprised: ACACB, ACE,
ACTN4, ADIPOQ, ADM, AFF3, AGTR1, APOL1, CARSCNDP1, CNDP2, CPS1, CPVL, CPVL, CHN2, CYBA-ELMO1,
ENPP1, ERBB4, FABP2, FRMD3, GLUT1, IRS2, MYO16,
LIMK2, MCTP2, MYO16, MYH9, NCALD, NCK1, NOS3,
NPHS1, NPHS2, NPPB, PLCE1, PPARγ2, PVT1, RAGE,
RGMA, RPS12, SFI1, SHROOM3, TMEM22, TNFRSF1A
and TRPC6.
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Accordingly, 145 patients with TD2M were identified with
DKD, while 265 were identified as disease free (tables 1
and 2). The remaining 80 patients could not be classified
with or without DKD at the time of the study and were
excluded from subsequent analyses.
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Covariate

OR

95% CI

P values

Age
Gender

0.99
0.90

0.96 to 1.04
0.34 to 2.36

0.80
0.83

BMI

1.02

0.97 to 1.08

0.49

Hypertension

2.00

0.60 to 6.74

0.26

HbA1c

0.86

0.69 to 1.07

0.19

Cholesterol

0.59

0.19 to 1.76

0.34

Triglyceride

1.09

0.62 to 1.94

0.76

HDL-cholesterol

1.25

0.64 to 2.45

0.52

LDL-cholesterol

1.38

0.42 to 4.57

0.60

Smoking history

0.80

0.34 to 1.87

0.61

Creatinine

1.03

1.00 to 1.06

0.03

Urea

1.13

0.92 to 1.38

0.26

eGFR

0.97

0.94 to 1.00

0.09

5–10

0.75

0.26 to 2.16

0.59

11–15

1.49

0.56 to 3.91

0.42

16–20
>20

3.35
3.12

1.22 to 9.23
1.21 to 8.02

0.02
0.02

Diabetes
duration (years)*

*Diabetes duration reference is duration ≤5 years
BMI, body mass index; eGFR, estimated glomerular filtration rate;
HDL, high-density lipoprotein; LDL, low-density lipoprotein; T2DM,
type 2 diabetes mellitus; UAE, United Arab Emirates.

Statistical power considerations
The current study had a power ~57%. This is based on the
current sample size (145 with DKD vs 265 without DKD),
prevalence of DKD ~20% (depending on reference #2),
genotype risk (OR)=1.5, significance level of 0.0008
(following the correction of multiple testing using the
Bonferroni correction), disease allele frequency=0.5 and
multiplicative model. Calculations were verified using the
Genetic Association Study Power Calculator (http://csg.
sph.umich.edu//abecasis/cats/gas_power_calculator/
index.html).

eGFR levels, 474 for serum creatinine levels and 450 for
blood urea levels. Among the 490 patients, 410 had clear
classifications for the diagnosis of kidney disease (145
patients with DKD and 265 without DKD) according to
the adopted diagnostic criteria (references #33 and #34)
and/or patient medical records. The possible covariates
that may affect the genetic associations for trait analyses
are summarised in table 1.
Clinical and laboratory characteristics of patients with and
without DKD
Both patient groups (with or without kidney disease) had
poor glycaemic control with blood glucose levels above
8 mmol/L. A comparison of patients with DKD to those
without DKD indicated that the majority of patients with
DKD were men (52% vs 38% for controls), older in age
(67 vs 59 years), had significant rates of comorbidities,
such as hypertension and dyslipidaemia, and had a longer
T2DM duration (16 vs 10 years). A clear decline in renal
function indices was also observed in patients with DKD
compared with those without DKD, as indicated by the
significantly higher rates of ACR, urea and creatinine,
and significantly lower eGFR (table 2). However, patients
with DKD tended to have lower low-density lipoprotein-cholesterol results as compared with those without
DKD, which suggests that these patients were more likely
to have received intensive statin therapy (table 2).
Factors associated with developing DKD in Emirati patients
with T2DM
Table 3 shows that T2DM duration was the single factor
that significantly contributed to the development of DKD.
Increased risk for DKD was significantly associated with
the increasing duration of T2DM, cumulatively, up to
20 years of duration. At a T2DM duration ≥20 years, the
DKD risk stabilised at approximately 3.12 times higher as
compared with patients with duration ≤5 years (p=0.02,
95% CI 1.21 to 8.02). Although the levels of serum creatinine indicated a significant difference between no DKD
and DKD patients (p=0.03), the OR of 1.03 showed no
increased risk (table 3).

Results
Baseline data of kidney function associated traits and SNPs
selection
Of the 490 patients with T2DM that were recruited for
this study, 115 patients were tested for genetic associations with the albumin-to-creatinine ratio, 328 for vitamin
D levels (measured as 25-OH cholecalciferol), 395 for

Genetic associations of renal function associated traits in
Emirati patients
The results of genetic associations for each tested renal
function trait are shown in table 4. In summary, no association passed the Bonferroni correction for multiple
testing. However, we report here the most suggestive associations which point to replications of previous reports.
For blood urea, the best observed association was with
rs11868441 in breast carcinoma-amplified sequence
3 (BCAS3) (effect size: −0.038 log per allele A, p=0.014),
followed by multiple SNPs in the R-Spondin 3 (RSPO3)
gene.
For serum creatinine, two SNPs (rs6999484 and
rs1705699) in the intergenic region between STC1 and
ADAM28 showed the best associations with similar effect
sizes (0.03 log per one copy of the corresponding minor
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Table 3 Risk factors for the development of kidney disease
in patients with T2DM from the UAE
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SNP

Chr: BP

Gene

A1/A2*

MAF_%

Beta†

SE

P value

rs11868441

17: 59239221

BCAS3

A/G

30.1

−0.038

0.015

0.014

rs1892172

6: 127476516

RSPO3

T/C

46.9

0.031

0.014

0.028

rs4644087

6: 127481154

RSPO3

C/A

46.8

0.030

0.014

0.03

rs4382293

6: 127475433

RSPO3

G/A

47.0

0.030

0.014

0.03

rs2489629

6: 127476717

RSPO3

G/A

44.9

−0.029

0.014

0.039

Blood urea

Serum creatinine
rs6999484

8: 23728271

STC1-ADAM28

A/G

23.8

0.033

0.011

0.003

rs1705699

8: 23781453

STC1-ADAM28

G/A

24.2

0.031

0.011

0.005

rs2828785

21: 25437505

-

A/G

19.9

−0.030

0.011

0.008

rs11227279

11: 65495211

KRT8P26-AP5B1

A/G

28.4

−0.024

0.010

0.019

rs7785065

7: 32915204

KBTBD2

A/C

43.5

0.022

0.010

0.022

rs4859682

4: 77410318

SHROOM3

A/C

25.7

0.021

0.010

0.034

rs1031755

15: 53951435

WDR72

C/A

11.7

−0.029

0.014

0.038

rs7740534

6: 25077179

-

C/A

9.6

−0.032

0.015

0.042

rs2168785

17: 37407135

MED1

G/A

28.2

−4.299

1.754

0.015

rs12452509

17: 37574722

MED1

G/A

28.1

−4.232

1.757

0.017

rs4776168

15: 53936907

WDR72

G/A

10.8

5.828

2.699

0.031

rs10518733

15: 53940307

WDR72

C/A

10.8

5.828

2.699

0.031
0.035

Estimated glomerular
filtration rate

rs7541937

1: 35341982

DLGAP3

C/A

44.0

3.590

1.693

rs10032549

4: 77398015

SHROOM3

G/A

32.2

−3.655

1.750

0.037

rs2484639

1: 243462367

SDCCAG8

A/G

43.5

3.378

1.656

0.042

rs1801725

3: 122003757

CASR

A/C

22.6

−6.923

2.584

0.008

rs1155563

4: 72643488

GC

G/A

18.9

−6.951

2.608

0.008

rs12794714

11: 14913575

CYP2R1

A/G

41.5

−5.110

2.099

0.015

rs10500804

11: 14910273

CYP2R1

C/A

42.2

−5.004

2.060

0.016

18: 3043516

LPIN2-MYOM1

G/A

17.8

−0.323

0.144

0.027

Vitamin D(25-OH
cholecalciferol)

Albumin:creatinine ratio
rs4528660

*A1/A2: minor to major alleles.
†Beta: regression coefficient for the linear regression model, calculated based on A1 (the minor allele).
BP, base pair position; Chr, chromosome; MAF, minor allele frequency; SNP, single nucleotide polymorphism.

allele), followed by SNP rs2828785 (p=0.008, effect
size=−0.030 log per one copy of allele A), which is located
in the non-coding gene area on chromosome 21. In addition, multiple genetic areas were also indicated, although
with less significant associations.
eGFR levels were significantly associated with SNPs
within the MED1 gene, rs2168785 with effect size of −4.299
per allele G and rs12452509 with effect size of −4.232 per
allele G and p=0.015 and 0.017, respectively. In addition,
the SNPs in two genetic regions, WDR72 and SHROOM3,
which are associated with serum creatinine levels, were
also associated with eGFR levels, indicating a strong link
to renal function.
Vitamin D levels were associated with three genetic
regions including rs1801725 in CARS (effect size:
−6.923 per allele A, p=0.0078), rs1155563 in GC (effect
size: −6.951, p=0.0081) and two SNPs, rs12794714 and

rs10500804, in cytochrome P450 family 2 subfamily R
member 1 (CYP2R1) with effect sizes of approximately
−5.0 and p values of 0.015 and 0.016, respectively.
One SNP, rs4528660, which is located in the intergenic
region between LPIN2 and MYOM1 (effect size: −0.323
log per allele A, p=0.027) was strongly associated with the
albumin-to-creatinine ratio.
These data demonstrated that renal function traits are
linked to several loci in the UAE population and that
some loci (eg, WDR27 and SHROOM3) are linked to more
than one trait.
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Genetic associations of DKD in Emirati patients
Sixty-three SNPs in 43 genetic loci, which have previously been linked to CKD or DKD, were included in our
genetic analyses of DKD (145 patients with DKD versus
265 without DKD). A logistic regression model including
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Table 4 Results of genetic association analyses of different renal function indices
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MAF
SNP

Chr: BP

Gene

A1/A2*

DKD (n=145)

No DKD (n=265) Punadjusted

Padjusted

OR (95% CI)

rs7422339

2: 211540507

CPS1

A/C

35.8%

27.9%

0.019

0.20

1.25 (0.89 to 1.75)

rs4859682

4: 77410318

SHROOM3

A/C

29.0%

21.9%

0.024

0.04

1.46 (1.01 to 2.10)

*A1/A2: minor to major alleles.
BP, base pair position; Chr, chromosome; CKD, chronic kidney disease; CPS1, carbamoyl-phosphate synthase; DKD, diabetic kidney disease; MAF, minor allele
frequency; SHROOM3, shroom family member 3; SNPs, single nucleotide polymorphisms; UAE, United Arab Emirates.

five possible covariates that may affect the development
of kidney disease was applied (table 1). As depicted in
table 5, the unadjusted analyses indicates two associations
in CPS1 (rs7422339, p=0.019) and SHROOM3 (rs4859682,
p=0.024), respectively. Following the adjustment for
possible covariates, only the SHROOM3 rs4859682
remained significant (p=0.04, OR=1.46). This confirms
that SHROOM3 is a string risk locus for DKD, considering
similar associations with serum creatinine and eGFR
levels.
Discussion
A combination of environmental and clinical factors in
genetically predisposed individuals have been suggested
to be involved in DKD, including persistent hyperglycaemia, arterial hypertension and/or dyslipidaemia.37 In
addition, familial aggregation of nephropathy in T2DM
has been reported in several populations.38 Therefore,
understanding the complex multifactorial interactions
between genetic, clinical and traditional kidney disease
risk factors can provide insight into novel drugs and
treatment strategies for DKD towards reducing the likelihood of developing ESRD. In this study, we investigated
whether the genetic markers that correspond to DKD and
renal function traits reported for different populations
are similar to the Arab population.
The current Emirati population sample indicated that
most patients with T2DM who developed DKD were males,
about 10 years older, had more frequent comorbidities,
specifically hypertension and showed a marked decline
in their renal function profiles, as compared with those
who did not develop the disease. However, patients with
T2DM who did not develop DKD still had higher rates
of comorbidities and poor diabetic control, in agreement
with our previous results.29 We also found that the duration of diabetes was the single factor that significantly
contributed to the development of kidney disease. Specifically, the risk of developing DKD became significant
when the duration of T2DM reached the 15-year mark.
This is in alignment with previous reports, which suggest
that patients with T2DM who do not develop signs of
kidney disease by 15 years’ duration of diabetes seem to
be protected, most likely due to genetic factors.39
The most notable finding of this study was the association of shroom family member 3 (SHROOM3) with serum
creatinine, eGFR and DKD. The minor allele for the
SNP rs4859682 (A) was observed to increase the serum

creatinine (0.021 log increase per one copy) and also to
increase the risk for DKD (OR=1.46). SHROOM3 was first
reported to be associated with eGFR levels in patients with
DKD,13 then with serum creatinine40 and serum magnesium levels.41 This association was further replicated in
different ethnicities.19 42 The SHROOM3 gene product is
expressed in the human kidney and is reported to play an
important role in epithelial cell shape regulation,43 as well
as the maintenance of the glomerular filtration barrier
integrity.44 Defective Shroom3 protein leads to decreased
actin organisation and affects the mechanical characteristics and integrity of the glomerular podocyte resulting
in thinning of the glomerular filtration membrane.44
Additionally, Shroom3 heterozygous (Shroom3Gt/+) mice
showed developmental irregularities that manifested
as adult-onset glomerulosclerosis and proteinuria.45
Furthermore, genetic variants (such as the intronic
variant rs17319721) were found to contribute to kidney
allograft injury and the development of fibrosis through
a mechanism involving transforming growth factor beta
(TGF-β) signalling.46 Although the variant rs17319721
was not found in our dataset, it is highly linked to the
SNP rs4859682 (r2=0.85, D′=1), which was reported in this
study to increase the risk for DKD and affect the levels of
serum creatinine. Overall, this suggests that SHROOM3
may be considered as a multiethnic risk gene for DKD
and associated kidney function traits in various populations, including the Arabs who inhabit the UAE.
Similarly, the two loci, WD repeat domain 72 (WDR72),
associated with eGFR and serum creatinine levels), and
BCAS3, associated with blood urea levels), are also wellknown transethnic renal function traits loci.47 WDR72, in
particular, has been well studied in association with kidney
function traits and pathologies. For instance, WDR72 has
been reported to be associated with creatinine production or secretion,48 as well as signal transduction, cell cycle
regulation and vesicular trafficking that affects podocyte
activity, reduced eGFR and progression of CKD.49 In addition, RSPO3 has been previously reported to be associated
with blood urea nitrogen concentration, in line with the
results of the current study.42 The association of rs4528660
near MYOM1 (Myomesin 1) with the albumin-to-creatinine ratio is also in agreement with previous work, which
links this locus to albuminuria in patients with diabetes.50
The current analyses also replicated the associations of
calcium-sensing receptor (CASR), group-specific component (GC) (vitamin D-binding protein, also known
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Table 5 Association between SNPs linked to CKD and DKD patients from the UAE
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as GC-globulin) and CYP2R1 with levels of vitamin
D.51 These genes encode proteins that are involved in
vitamin D function, including activation by hydroxylation (CYP2R1), transportation (GC) and serum calcium
level sensoring (CASR).51 They have also been associated
with calcium–vitamin D physiology and pathology, such
as serum calcium levels, familial hypocalciuric hypercalcaemia, tertiary hyperparathyroidism and vitamin D deficiency presenting as rickets (see OMIM entries: CARS:
601199; CYP2R1: 608713; and GC: 139200). For instance,
CASR protein is expressed in the kidney among other
tissue and regulates ion metabolism including calcium
and magnesium. Mutations in CASR lead to abnormalities in the regulation of the parathyroid gland and renal
function causing hypercalcaemia and increased blood
pressure, which in turn may affect kidney function.52
Similarly, GC proteins bind actin and work as actin scavengers (as such GC may play a role in podocyte integrity),
as well as a binding site for vitamin D. The GC protein is
the precursor to the Gc-macrophage activating factor, a
macrophage activator and suggests, together with vitamin
D, that GC has an important role in the immune function
and pathogenesis of CKD.53 Vitamin D is hydroxylated
at the C25 position by specific hydroxylase coded by the
CYP2R1 gene to 25-hydroxyvitamin D, which is the main
circulating form of vitamin D. The low levels of vitamin D
observed in CKD, due to reduced CYP2R1 production by
the liver or due to a mutation in the gene, disturb calcium
balance and lead to hyperparathyroidism. Conversely,
the loss of renal protection caused by vitamin D and the
increase in the renin–angiotensin pathway leads to hypertension that further advances kidney disease.54 Furthermore, these genes have recently been shown to influence
the outcome of vitamin D3 supplementation which, in the
Arab context, is an important finding of our study.55
In summary, this work presents the first study to investigate the clinical and genetic factors influencing kidney
function traits and DKD in a population of Arab ancestry.
The results demonstrate that the duration of T2DM is
the single most important risk factor for DKD development in patients with T2DM in the UAE. Our study
highlights that several genetic loci, which have been
previously linked to renal function associated traits,
are shared between diverse ethnic groups. As such, we
have replicated previous findings of the association of
SHROOM3 with DKD. The logistic analyses performed
here did not include treatment modalities since most
of the patients had multiple conditions and underwent multiple treatments, which makes logistic regression largely unstable and difficult to interpret. A larger
population sample across the Middle East is now being
considered to confirm the extent of the shared genetic
predisposition reported in the current study. Considering the high prevalence of T2DM in this population
and the recent evidence of genomic structure variations
among different ethnic groups, more genetic-driven
population studies are warranted towards effective genetically guided personalised medicine.
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